livercancerdrug
-
HLB's Liver Cancer Drug Listed as First-Line Treatment in ESMO Guidelines Ahead of FDA ApprovalBig Tech 2025. 2. 27. 12:42
· ESMO strongly recommends rivoceranib and camrelizumab as a first-line treatment for liver cancer. SEOUL, South Korea, February 27, 2025 (IT Times) – HLB announced that its liver cancer treatment, rivoceranib and camrelizumab, has been listed as a first-line treatment in the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis and treatment of hepatocellul..